Chalcones Derivatives Acting as Cell Cycle Blockers: Potential Anti Cancer Drugs?

2009 ◽  
Vol 10 (4) ◽  
pp. 363-371 ◽  
Author(s):  
Boumendjel Ahcene ◽  
Ronot Xavier ◽  
Boutonnat Jean ◽  
Ahcene Boumendjel ◽  
Xavier Ronot ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Cancer Drugs ◽  
Anti Cancer

Mapping Binding Sites of Potential Anti-Cancer Drugs on Tubulin

2000 ◽  
Vol 6 (S2) ◽  
pp. 236-237
Author(s):  
Huilin Li ◽  
Eva Nogales ◽  
Kenneth H. Downing
Keyword(s):  
Cell Cycle ◽  
Side Effects ◽  
Binding Sites ◽  
Microtubule Dynamics ◽  
Cancer Drugs ◽  
Substantial Fraction ◽  
Dynamic Activity ◽  
Anti Cancer ◽  
Main Protein ◽  
Induction Of Apoptosis

Microtubules are involved in many activities within the cell that require highly dynamic activity. For examples, microtubules can grow and shrink as they explore the cell, and the entire microtubule cytoskeleton is restructured as cells prepare for division. Interfering with microtubule dynamics can have serious consequences for the health of the cell, especially in cells that are rapidly dividing. The result of disrupting the normal dynamics is generally an interruption of the cell cycle and consequent induction of apoptosis. This behavior has been exploited with a number of anti-cancer drugs that target tubulin, the main protein in microtubules. Drugs are currently in use that either stabilize or destabilize microtubules. Among the most widely used is Taxol, one of the microtubule stabilizing drugs. Because Taxol produces a range of serious side effects and a substantial fraction of patients treated with Taxol eventually develop resistance to the drug, there is an active search for other drugs that might be more selective and less prone to resistance.

scholarly journals Using Immunocytochemistry and Fluorescence Microscopy Imaging to Explore the Mechanism of Action of Anti-Cancer Drugs on the Cell Cycle

CourseSource ◽  
2020 ◽  
Vol 7 ◽  
Author(s):  
Allison R. D'Costa ◽  
David W. Barnes ◽  
Alessandra Barrera ◽  
Jennifer Hurst-Kennedy ◽  
Latanya Hammonds-Odie
Keyword(s):  
Cell Cycle ◽  
Fluorescence Microscopy ◽  
Mechanism Of Action ◽  
Cancer Drugs ◽  
Microscopy Imaging ◽  
Anti Cancer

scholarly journals In Vivo Analysis of Drosophila Deoxyribonucleoside Kinase Function in Cell Cycle, Cell Survival and Anti-Cancer Drugs Resistance

Cell Cycle ◽  
2006 ◽  
Vol 5 (7) ◽  
pp. 740-749 ◽  
Author(s):  
Kevin Legent ◽  
Magali Mas ◽  
Annie Dutriaux ◽  
Solange Bertrandy ◽  
Domenico Flagiello ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Cell Survival ◽  
Cancer Drugs ◽  
Anti Cancer ◽  
In Vivo Analysis

A Case of Malignant Melanoma Treated with a Combination of Anti-Cancer Drugs and Biological Response Modifiers.

1993 ◽  
Vol 55 (1) ◽  
pp. 43-46
Author(s):  
Jun YOSHIDA ◽  
Juichiro NAKAYAMA ◽  
Nobuyuki SHIMIZU ◽  
Shonosuke NAGAE ◽  
Yoshiaki HORI
Keyword(s):  
Malignant Melanoma ◽  
Biological Response ◽  
Biological Response Modifiers ◽  
Cancer Drugs ◽  
Anti Cancer

Cancer Treatment with Liposomes Based Drugs and Genes Co-delivery Systems

2018 ◽  
Vol 25 (28) ◽  
pp. 3319-3332 ◽  
Author(s):  
Chuanmin Zhang ◽  
Shubiao Zhang ◽  
Defu Zhi ◽  
Jingnan Cui
Keyword(s):  
Cell Cycle ◽  
Cancer Cells ◽  
Synergistic Effects ◽  
Resistance Mechanisms ◽  
Delivery Systems ◽  
Cell Cycle Checkpoints ◽  
Drug Efflux ◽  
Cancer Resistance ◽  
Cancer Models ◽  
Anti Cancer

There are several mechanisms by which cancer cells develop resistance to treatments, including increasing anti-apoptosis, increasing drug efflux, inducing angiogenesis, enhancing DNA repair and altering cell cycle checkpoints. The drugs are hard to reach curative effects due to these resistance mechanisms. It has been suggested that liposomes based co-delivery systems, which can deliver drugs and genes to the same tumor cells and exhibit synergistic anti-cancer effects, could be used to overcome the resistance of cancer cells. As the co-delivery systems could simultaneously block two or more pathways, this might promote the death of cancer cells by sensitizing cells to death stimuli. This article provides a brief review on the liposomes based co-delivery systems to overcome cancer resistance by the synergistic effects of drugs and genes. Particularly, the synergistic effects of combinatorial anticancer drugs and genes in various cancer models employing multifunctional liposomes based co-delivery systems have been discussed. This review also gives new insights into the challenges of liposomes based co-delivery systems in the field of cancer therapy, by which we hope to provide some suggestions on the development of liposomes based co-delivery systems.

Current Scenario in Structure and Ligand-Based Drug Design on Anti-colon Cancer Drugs

2019 ◽  
Vol 24 (32) ◽  
pp. 3829-3841 ◽  
Author(s):  
Lakshmanan Loganathan ◽  
Karthikeyan Muthusamy
Keyword(s):  
Drug Discovery ◽  
Drug Design ◽  
Anticancer Agent ◽  
Computational Power ◽  
Cancer Drugs ◽  
Recent Advances ◽  
Anti Cancer ◽  
Drug Designing ◽  
Current Scenario ◽  
Molecular Modeling Studies

Worldwide, colorectal cancer takes up the third position in commonly detected cancer and fourth in cancer mortality. Recent progress in molecular modeling studies has led to significant success in drug discovery using structure and ligand-based methods. This study highlights aspects of the anticancer drug design. The structure and ligand-based drug design are discussed to investigate the molecular and quantum mechanics in anti-cancer drugs. Recent advances in anticancer agent identification driven by structural and molecular insights are presented. As a result, the recent advances in the field and the current scenario in drug designing of cancer drugs are discussed. This review provides information on how cancer drugs were formulated and identified using computational power by the drug discovery society.

Molecular Mechanisms of Thymoquinone as Anticancer agent

2020 ◽  
Vol 23 ◽  
Author(s):  
Fatma Ismail Alhmied ◽  
Ali Hassan Alammar ◽  
Bayan Mohammed Alsultan ◽  
Marooj Alshehri ◽  
Faheem Hyder Pottoo
Keyword(s):  
Breast Cancer ◽  
Cell Cycle ◽  
Cell Cycle Arrest ◽  
Human Breast Cancer ◽  
Phase Cell ◽  
Cycle Phase ◽  
Human Breast ◽  
Cycle Arrest ◽  
Phase Arrest ◽  
Anti Cancer

Abstract:: Thymoquinone (TQ), the bioactive constituent of Nigella Sativa seeds is a well-known natural compound for the management of several types of cancers. The anti-cancer properties of thymoquinone are thought to be operated via intervening with various oncogenic pathways including cell cycle arrest, prevention of inflammation and oxidative stress, induction of invasion, metastasis, inhibition of angiogenesis, and apoptosis. As well as up-regulation and down-regulation of specific tumor suppressor genes and tumor promoting genes, respectively. Proliferation of various tumor cells is inhibited by TQ via induction of cell cycle arrest, disruption of the microtubule organization, and down regulating cell survival protein expression. TQ induces G1 phase cell cycle arrest in human breast cancer, colon cancer and osteosarcoma cells through inhibiting the activation of cyclin E or cyclin D and up-regulating p27and p21 a cyclin dependent kinase (Cdk) inhibitor. TQ concentration is a significant factor in targeting a particular cell cycle phase. While high concentration of TQ induced G2 phase arrest in human breast cancer (MCF-7) cells, low concentration causes S phase arrest. This review article provides mechanistic insights into the anti-cancer properties of thymoquinone.

Fanconi Anemia DNA Repair Pathway as a New Mechanism to Exploit Cancer Drug Resistance

2020 ◽  
Vol 20 (9) ◽  
pp. 779-787
Author(s):  
Kajal Ghosal ◽  
Christian Agatemor ◽  
Richard I. Han ◽  
Amy T. Ku ◽  
Sabu Thomas ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Dna Repair ◽  
Fanconi Anemia ◽  
Cancer Drug ◽  
Drug Resistant ◽  
Cancer Drugs ◽  
Repair Pathway ◽  
Cancer Drug Resistance ◽  
Anti Cancer ◽  
Cancerous Cells

Chemotherapy employs anti-cancer drugs to stop the growth of cancerous cells, but one common obstacle to the success is the development of chemoresistance, which leads to failure of the previously effective anti-cancer drugs. Resistance arises from different mechanistic pathways, and in this critical review, we focus on the Fanconi Anemia (FA) pathway in chemoresistance. This pathway has yet to be intensively researched by mainstream cancer researchers. This review aims to inspire a new thrust toward the contribution of the FA pathway to drug resistance in cancer. We believe an indepth understanding of this pathway will open new frontiers to effectively treat drug-resistant cancer.

Sign in / Sign up

Export Citation Format

Share Document